Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

Seeking Alpha / 1 Views

Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye

Comments